Novartis Ag (NVSEF) Gross Margin (2009 - 2025)

Novartis Ag has disclosed Gross Margin across 15 years of filings, most recently posting 81.93% for Q2 2025.

• Gross Margin for Q2 2025 came in at 81.93%, up 441.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 77.1% (down 1074805.0% YoY), and the FY2025 annual result was 78.81%, up 151.0% from the prior year.
• Gross Margin came in at 81.93% for Q2 2025 at Novartis Ag, up from 76.92% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 1543209.88% in Q1 2023 to a low of 393700.79% in Q4 2022.
• The 5-year median for Gross Margin is 73.25% (2023), against an average of 112408.74%.
• Across the five-year window, Gross Margin slumped 756301592 bps in 2021 and surged 154319665 bps in 2023, its largest moves.
• Novartis Ag's Gross Margin stood at 0.06% in 2021, then tumbled by 713357805 bps to 393700.79% in 2022, then soared by 100 bps to 74.02% in 2023, then rose by 4 bps to 76.92% in 2024, then gained by 7 bps to 81.93% in 2025.
• The last three Gross Margin figures came in at 81.93% (Q2 2025), 76.92% (Q4 2024), and 77.52% (Q2 2024), per Business Quant data.